Online citations, reference lists, and bibliographies.
← Back to Search

Effectiveness Of Botulinum Toxin Therapy For Essential Blepharospasm.

P. Engstrom, J. B. Arnoult, M. Mazow, T. Prager, R. B. Wilkins, W. Byrd, R. J. Hofmann
Published 1987 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
The effectiveness of Botulinum toxin (Oculinum) therapy in 76 patients with the diagnosis of essential blepharospasm was analyzed. Botulinum offers relief to almost all patients suffering from essential blepharospasm, however, this relief is usually temporary. The response time for repeated treatments tended to be longer than the first treatment. Patients with mild blepharospasm responded significantly longer to Botulinum injection, than those with severe spasms. The response to Botulinum was not significantly different in patients with Meige syndrome than in patients with only essential blepharospasm. Patients previously treated surgically for essential blepharospasm did not respond differently than those patients with no previous surgical therapy. The authors believe that Botulinum toxin injection is an effective, although temporary, mode of therapy for the signs and symptoms of this focal dystonia. The authors recognize that there may be psychologic factors affecting the response.
This paper references



This paper is referenced by
10.1007/978-3-319-56038-0_8
Clinical Uses of the Botulinum Toxin and Ophthalmology
J. Galvin (2018)
10.1016/S0002-9394(03)00075-8
Quantitative changes in botulinum toxin a treatment over time in patients with essential blepharospasm and idiopathic hemifacial spasm.
M. Snir (2003)
10.1016/B978-0-7506-9322-6.50028-3
CHAPTER 19 – Diseases of the Eyelids
J. D. Bartlett (1989)
10.1007/s00702-010-0546-9
Difficulties with differentiating botulinum toxin treatment effects in essential blepharospasm
B. Wabbels (2010)
10.1016/S0025-6196(12)64977-5
Treatment of blepharospasm with botulinum toxin.
R. H. Kennedy (1989)
10.1111/J.1444-0938.1997.TB04852.X
Review of facial muscle spasms
P. Kiely (1997)
10.1016/S0161-6420(88)32977-5
Long-term results and complications of botulinum A toxin in the treatment of blepharospasm.
J. Dutton (1988)
BOTULINUM TOXIN: A POISON FOR SOME, A POTION IN OCULOPLASTICS
D. Yip (2002)
10.1007/BF01646651
New approaches in the treatment of the dystonias
N. Diederich (2005)
The pupillary effects of retrobulbar injection of botulinum toxin A (oculinum) in albino rats.
Y. Levy (1991)
10.1016/S0161-6420(96)30773-2
Strabismus and the Academy.
J. Mims (1996)
10.1136/BJO.75.12.737
Natural history of treatment of facial dyskinesias with botulinum toxin: a study of 50 consecutive patients over seven years.
J. Mauriello (1991)
10.1016/0002-9394(88)90016-5
Negative antibody response to long-term treatment of facial spasm with botulinum toxin.
R. Gonnering (1988)
10.1007/PL00007813
Botulinum toxin: evidence-based medicine criteria in blepharospasm and hemifacial spasm
W. Jost (2001)
10.1007/s12640-012-9314-y
Efficacy and Safety of Long-term Botulinum Toxin Treatment in Craniocervical Dystonia: A Systematic Review
C. Colosimo (2012)
10.1590/S0034-72802009000500008
Estudo comparativo da ação da toxina botulínica tipo A e da crotoxina sobre as células satélites da musculatura extrínseca ocular em modelo animal
Marta Halfeld Ferrari Alves Lacordia (2009)
10.1007/BF03163766
Indikation zur perioperativen Behandlung des spastischen Entropiums mit Botulinum Toxin-A
A. Kuchar (2009)
10.1016/j.jfo.2020.06.001
Blepharospasm, dry eye and extractable nuclear antigen antibodies.
B. Girard (2020)
10.1016/b978-1-4160-4673-8.10007-5
Drug-Induced Ocular Side Effects
F. Fraunfelder (1996)
10.1038/eye.2009.192
Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation indexes
S. Cillino (2010)
10.1111/j.1600-0404.1996.tb07053.x
Botulinum toxin A injection in the treatment of hemifacial spasm
R. S. Chen (1996)
10.1159/000026648
The Control of Blepharospasm by Essential Fatty Acids
D. Mostofsky (2000)
10.1097/IOP.0b013e31816386e1
Pain Relief in Patients Receiving Periocular Botulinum Toxin A
Andrew R. Harrison (2008)
10.1007/978-1-4614-4466-4_16
Spastic Facial Muscle Disorders
Juwan Park (2012)
10.1007/978-3-030-50691-9_13
Botulinum Toxin Treatment in Ophthalmology and Ophthalmic Surgery
Keya Jafari (2020)
10.1001/ARCHOPHT.124.1.116
Health-related quality of life and psychosocial characteristics of patients with benign essential blepharospasm.
T. A. Hall (2006)
10.1016/S0008-4182(01)80084-3
Botulinum toxin for blepharospasm and hemifacial spasm: stability of duration of effect and dosage over time.
G. Drummond (2001)
10.1016/S0161-6420(95)30757-9
Long-term changes in duration of relief with botulinum toxin treatment of essential blepharospasm and hemifacial spasm.
J. Ainsworth (1995)
10.1007/978-3-319-56038-0
Botulinum Toxin Treatment in Clinical Medicine
B. Jabbari (2018)
10.1001/ARCHOTOL.1988.01860240057024
Management of facial spasm with Clostridium botulinum toxin, type A (Oculinum)
A. W. Biglan (1988)
10.1016/0039-6257(91)90207-V
Botulinum A toxin (Oculinum) in ophthalmology.
M. Osako (1991)
10.1007/s12640-009-9023-3
Fifteen-Year Experience in Treating Blepharospasm with Botox or Dysport: Same Toxin, Two Drugs
A. R. Bentivoglio (2009)
See more
Semantic Scholar Logo Some data provided by SemanticScholar